October 17, 2019
Teva Pharmaceuticals USA is recalling a single lot of Matzim LA (diltiazem hydrochloride) extended-release tablets, 240 mg. According to the October 16, 2019, US Food and Drug Administration (FDA) Enforcement Report, the “lot [was] not intended for commercial distribution.”
The recall affects 5849 bottles, each containing 30 Matzim LA tablets (NDC 52544-692-30), from lot 1344864A (Exp. 10/20). Actavis Pharma Inc. distributed the tablets to wholesalers and retailers that may have further distributed them throughout the United States, including in Hawaii and Puerto Rico.
Teva Pharmaceuticals voluntarily initiated the recall September 6, 2019. On October 9, 2019, the FDA designated the recall Class III, suggesting use of the recalled drugs is not likely to cause harm.
Matzim LA is a prescription calcium channel blocker used to treat hypertension and angina.